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Introduction
Clinical interest in the utility of non-invasive measurement 
of central aortic pressure (CAP) has heightened in recent 
years.1 This is due, in part, to the development of simple, 
robust methods for evaluating this clinical parameter,2,3 and 
also to the emergence of data demonstrating that central 
pressure may be a better marker of risk for developing car-
diovascular pathologies and clinical outcomes than con-
ventional assessment of brachial pressure.4,5 Other key 
studies have also established the concept of differential 
effects of blood pressure (BP) lowering treatments on bra-
chial and central pressure, promoting calls for the routine 
incorporation of central BP measurement in clinical trials.6 
More recently, the feasibility of monitoring 24-hour ambu-
latory central aortic pressure was reported.7 This has further 
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extended the potential clinical utility of central pressure 
monitoring.
Whilst the influence of drug treatment on both brachial 
and central pressure has been extensively discussed,8 the 
influence of drug treatment withdrawal on seated central 
pressure is not yet reported. Since missed medication 
doses are a frequent occurrence during the treatment of 
elevated BP, it is important to verify the consequences on 
central aortic pressure in comparison to what has been 
described for peripheral blood pressure.9,10 It is possible 
that treatment withdrawal could change the relationship 
between brachial and central pressure, effects which might 
not be apparent from monitoring brachial pressure alone.
Two different strategies for lowering BP via inhibition 
of the renin–angiotensin–aldosterone system (RAAS) were 
studied. We compared the effects of withdrawal following 
prior treatment with either aliskiren, a direct renin inhibitor, 
or telmisartan, an angiotensin receptor blocker (ARB), both 
known for their long-lasting efficacy.11,12 The primary 
focus of this study was on the 7-day treatment withdrawal 
period, following a 12-week treatment period, evaluating 
the corresponding changes in brachial BP and central aortic 
systolic pressure (CASP), in patients with hypertension. 
The ASSERTIVE study previously reported more sustained 
control of Br-SBP with aliskiren versus telmisartan in 
patients with hypertension,13 following 7-days treatment 
withdrawal. In this ASSERTIVE sub-study, we hypothe-
sised that aliskiren would similarly exert more sustained 
control of CASP than telmisartan during treatment with-
drawal. Importantly, this paper reports, for the first time, 
the impact of treatment withdrawal on brachial BP and 
CASP in a randomised clinical trial of BP lowering.
Methods
Study design
This was a sub-study embedded within the AliSkiren Study 
of profound antihypERtensive efficacy in hyperTensIVE 
patients (ASSERTIVE), the design and primary results of 
which have been previously published.13 ASSERTIVE 
was a randomised, double-blind, double-dummy, parallel-
group, multi-centre study. Following a 2-week washout 
and 1- to 2-week placebo run-in period, patients were ran-
domised to 2 weeks of active treatment with either once-
daily aliskiren 150 mg or telmisartan 40 mg monotherapies, 
and then force-titrated to double the initial dose for 10 
weeks.
At the end of the 12-week treatment period, both drugs 
were replaced with placebo and brachial and central pres-
sures were measured at days 2 and 7 following treatment 
withdrawal. The present analysis focuses on the 7-day 
treatment withdrawal period. Details of the run-in and 
active treatment periods concerning sitting brachial and 
central pressure are presented in the online supplement.
Patients
The ASSERTIVE study included men or women ⩾18 
years, with essential hypertension (Grades 1–2), who met 
both of the following criteria at randomisation: office sys-
tolic BP (SBP) ⩾140 mmHg and <180 mmHg, and 24-hour 
mean ambulatory SBP (MASBP) ⩾135 mmHg. Major 
exclusion criteria included the following: severe hyperten-
sion (mean sitting SBP (msSBP) ⩾180 mmHg and/or 
mean sitting DBP (msDBP) ⩾110 mmHg), secondary 
hypertension, and pregnant women.
The trial was conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
Harmonisation Guidelines for Good Clinical Practice, and 
the US Code of Federal Regulations, Part 46, Protection of 
Human Subjects. The trial protocol was approved by inde-
pendent ethics committees at all centres, and written 
informed consent was obtained from each patient before 
participating in any trial procedures. The trial is registered 
as EudraCT no. 2008-007831-41 and on ClinicalTrials.gov 
under the code NCT00865020.
Participants in this ASSERTIVE sub-study were 
recruited from 45 out of the 111 ASSERTIVE study cen-
tres worldwide. All participants at each centre were invited 
to participate (mean participation 95±15% per centre) and 
this comprised the CASP randomised dataset (n = 303).
Study assessments
The primary endpoint for this analysis was to compare the 
sustained efficacy of prior treatment with aliskiren versus 
telmisartan on the change in seated CASP at day 7 follow-
ing treatment withdrawal. Other assessments included 
change in (1) seated CASP at day 2 following treatment 
withdrawal, (2) seated brachial BP at days 2 and 7 follow-
ing treatment withdrawal, (3) brachial ambulatory BP at 
day 7 following treatment withdrawal and (4) evaluation 
of biomarkers, plasma renin activity (PRA) and aldoster-
one across the treatment and 7-day withdrawal periods. 
Study visits were performed between 07:00 and 10:00 hrs 
so that set-up of ambulatory blood pressure measurements 
could be standardised across the study.
Brachial BP measurements
Seated brachial BP was measured at the end of the 12-week 
treatment period (baseline for this analysis) and on days 2 
and 7 following treatment withdrawal. Brachial BP was 
measured using a validated and automated BP monitor 
(Omron® HEM-705) with an appropriate cuff size, accord-
ing to the European Society for Hypertension Guidelines.15 
Briefly, the cuff device was applied on the non-dominant 
arm or the arm with the higher reading at screening if there 
was a clinically relevant difference (SBP ⩾10 mmHg and/
or DBP ⩾5 mmHg) between arms at the first study visit. 
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Three sitting BP measurements were taken at 1–2-minute 
intervals after the patient had been seated for 5 minutes. 
The mean of these readings was recorded as brachial BP.
CASP measurements
Seated CASP was measured at the end of the treatment 
period (baseline for this analysis) and on days 2 and 7 fol-
lowing treatment withdrawal, using the BPro™ device 
(HealthSTATS, Singapore). The BPro™ device uses 
applanation tonometry to capture high-fidelity radial artery 
pulse waveforms (RAPWF) at the wrist in blocks of 
10-second intervals. RAPWFs were calibrated to brachial 
BP measured in the same arm using the OMRON HEM-
705 device, immediately prior to waveform collection. 
CASP was derived from the calibrated RAPWFs using a 
validated algorithm.16
Ambulatory BP Monitoring
Twenty-four-hour brachial ambulatory BP monitoring 
(ABPM) using Spacelabs 90208 (Spacelabs Medical Inc., 
Redmond, Washington, USA) was performed at the end of 
the treatment period and on day 7 following withdrawal. 
ABPM sessions commenced between 7 a.m. and 10 a.m. 
and monitors were applied to the non-dominant arm of the 
patient, as previously described.13,17 Validity criteria for 
ABPM measurements included a minimum test duration 
of 24 hours, at least 70% of valid expected BP measure-
ments during the 24 hour duration, and no more than two 
non-consecutive hours without readings. If the ABPM 
measurement failed to achieve validity criteria at randomi-
sation, a repeat measurement was permitted within 24–72 
hours, provided the patient continued to receive placebo 
treatment.
Plasma renin activity and aldosterone levels
Blood samples were collected from a subset of patients 
prior to treatment initiation, at the end of the treatment 
period, and on day 7 following withdrawal. Blood samples 
were collected after a fast of at least 8 hours. EDTA sam-
ples were centrifuged within 5 minutes of collection and 
plasma was immediately frozen at −20°C for a maximum 
of 4 weeks, and then at −80°C at the central laboratory 
(Eurofins, Breda, The Netherlands), until assayed. The 
biomarker, PRA was assessed using RIA kits from 
DiaSorin (Stillwater, Minnesota, USA) and aldosterone 
was measured using RIA Coat-a-Count kits from Siemens 
(Deerfield, Illinois, USA).
Statistical analyses
In this sub-study, CASP was measured at sub-study base-
line (end of active treatment) and at days 2 and 7 following 
treatment withdrawal. However, not all patients had valid 
CASP measurements at all sub-study time points. Hence, 
two sets of patient populations, based on the extent of 
availability of their CASP data, were analysed. The CASP 
completer dataset was obtained from participants who had 
valid seated CASP measurements at all time points, i.e. at 
the end of the treatment period (baseline for this analysis) 
and on days 2 and 7 following treatment withdrawal. In 
addition, the CASP randomised dataset was obtained from 
participants who had a valid seated CASP measurement at 
least at one of the above mentioned time points. Changes 
from baseline in seated brachial SBP (msSBP), CASP, and 
MASBP were analysed using an analysis of covariance 
(ANCOVA) model with treatment, study region and gen-
der as factors and baseline mean arterial pressure as a 
covariate. The primary analysis focussed on changes in 
CASP from the end of the 12-week treatment period to 
days 2 and 7 of the treatment withdrawal period. Between-
treatment analysis was also performed for changes in 
msSBP, CASP and MASBP from baseline to end of the 
withdrawal period.
Results
Patient disposition
Of the 1359 patients who entered the placebo run-in period 
of the ASSERTIVE study, 822 were randomised to the 
aliskiren (n = 414) and telmisartan (n = 408) treatment 
groups. Of these patients, 303 (aliskiren, n = 157; telmisar-
tan, n = 146) participated in the central aortic pressure sub 
study (CASP randomised set), of whom 94 patients 
(aliskiren, n = 49; telmisartan, n = 45) had a valid CASP 
measurement completed at every time point across the 
treatment withdrawal period (CASP completer set).
Demographic and baseline characteristics
Demographic and baseline characteristics of the sub-study 
population were generally comparable between the aliskiren 
and telmisartan groups at randomisation for the CASP ran-
domised and CASP completer sets (Table 1).
Efficacy
Changes in seated brachial SBP
In the CASP randomised set, msSBP was similar between 
both treatment groups at baseline for the treatment with-
drawal period, i.e. at the end of the treatment period (aliskiren, 
138.8±13.8 mmHg versus telmisartan, 139.4±15.9 mmHg, 
as shown in Figure 1(a)). At day 2 of treatment withdrawal, 
change in msSBP was −0.8±0.9 mmHg with aliskiren and 
+2.1±0.9 mmHg with telmisartan, with a significant least 
squares mean (LSM) between-treatment difference of 
−2.9±1.3 mmHg (95% confidence interval (CI): −5.4, −0.4; 
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Table 1. Patient demographics and baseline characteristics by treatment (CASP completer set (n = 94) and CASP randomised set 
(n = 303)).
Characteristics at study entry Aliskiren 300 
mg
Telmisartan 
80 mg
Total Aliskiren 300 
mg
Telmisartan 
80 mg
Total
 (n = 49) (n = 45) (n = 94) (n = 157) (n = 146) (n = 303)
Age, years 56.9 (12.2) 52.3 (14.4) 54.6 (11.9) 54.5 (11.5) 53.5 (12.1) 54.0 (11.8)
Gender, n (%)  
 Male 22 (44.9) 22 (48.9) 44 (46.8) 71 (45.2) 74 (50.7) 145 (47.9)
 Female 27 (55.1) 23 (51.1) 50 (53.2) 86 (54.8) 72 (49.3) 158 (52.2)
Race, n (%)  
 Caucasian 26 (53.1) 21 (46.7) 47 (50.0) 97 (61.8) 87 (59.6) 184 (60.7)
 Asian 23 (46.9) 24 (53.3) 47 (50.0) 59 (37.6) 58 (39.7) 117 (38.6)
Diabetes, n (%) 8 (16.3) 7 (15.5) 15 (15.9) 19 (12.1) 20 (13.7) 39 (12.9)
Obesity, n (%)a 16 (32.7) 15 (33.3) 31 (33.0) 52 (33.1) 45 (30.8) 97 (32.0)
Weight, kg 75.8 (20.6) 76.5 (13.4) 76.1 (17.4) 77.4 (19.3) 78.2 (17.2) 77.8 (18.3)
BMI, kg/m2 28.3 (5.6) 28.2 (4.2) 28.2 (4.9) 28.4 (5.5) 28.2 (4.8) 28.3 (5.1)
Duration of hypertension, years 10.4 (9.4) 7.3 (6.7) 8.9 (8.3) 8.3 (7.8) 6.3 (5.5) 7.3 (6.8)
Mean sitting SBP, mmHg 153.7 (9.3) 156.7 (10.4) 155.1 (9.9) 154.6 (9.7) 155.9 (10.3) 155.2 (10)
Mean sitting DBP, mmHg 88.1 (9.4) 90.7 (8.6) 89.3 (9.0) 89.9 (9.8) 90.8 (8.8) 90.3 (9.3)
Mean ambulatory SBP, mmHg 147.3 (8.9) 148.7 (9.8) 148.0 (9.3) 146.2 (9.9) 147.7 (10.1) 146.9 (10.0)
CASP, mmHg 138.6 (12.1) 144.4 (11.0) 141.4 (11.8) 139.4 (12.1) 143.6 (12.2) 141.5 (12.3)
eGFR, mL/min/1.73 m2 83.9 (18.7) 90.5 (16.4) 87.1 (17.8) 86.9 (18.4) 88.4 (17.4) 87.6 (17.9)
Plasma renin activity, μg/l/h, 
geometric mean
0.65 (2.54) 0.59 (3.33) 0.62 (2.90) 0.72 (2.89) 0.56 (3.12) 0.64 (3.01)
Plasma aldosterone, pmol/l, 
geometric mean
171.19 (2.06) 165.52 (2.21) 168.55 (2.12) 174.54 (2.01) 161.58 (2.03) 168.26 (2.02)
Values are presented as mean (±SD), unless otherwise stated. aBMI ⩾ 30 kg/m2.
BMI, body mass index; BP, blood pressure; CASP, central aortic systolic pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtra-
tion rate; SBP, systolic blood pressure.
Figure 1. (a) Mean msSBP, (b) mean CASP, (c) LSM change in CASP and (d) mean MASBP from end of treatment to end of 
withdrawal (day 7 of withdrawal) for the CASP randomised set.
*p < 0.0001 (aliskiren vs. telmisartan). Error bars indicate 95% CI. CASP, central aortic systolic pressure; LSM, least-squares mean; MASBP, mean 
ambulatory SBP; msSBP, mean sitting systolic blood pressure.
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p = 0.026) in favour of aliskiren. Across the 7-day with-
drawal period, msSBP remained almost unchanged with 
aliskiren (+1.6±1.0 mmHg), but increased with telmisartan 
(+3.2±1.0 mmHg). However, LSM change between-treat-
ment difference (−1.6±1.5 mmHg; 95% CI: −4.5, 1.3) was 
not statistically significant (p = 0.275).
At baseline for the treatment withdrawal period, mean 
sitting brachial SBP (msSBP) was similar between treat-
ment groups in the CASP completer set (aliskiren, 
139.6±12.4 mmHg versus telmisartan, 140.2±14.9 mmHg) 
(Figure 2(a)). At day 2 of treatment withdrawal, msSBP 
changed little (−2.1±1.6 mmHg) with aliskiren, but 
increased with telmisartan (+4.1±1.6 mmHg). LSM change 
between-treatment difference (−6.3±2.3 mmHg; 95% CI: 
−10.8, −1.8) was statistically significant in favour of 
aliskiren (p = 0.006). Similarly, across the 7-day with-
drawal period, msSBP remained almost unchanged with 
aliskiren (−2.0±1.6 mmHg), but increased with telmisartan 
(+5.6±1.7 mmHg). LSM change between-treatment differ-
ence (−7.5±2.3 mmHg; 95% CI: −12.1, −3.0) was also sta-
tistically significant in favour of aliskiren (p = 0.001).
Changes in seated CASP
At baseline for the withdrawal period, mean seated CASP 
values were 129.9±16.2 mmHg versus 127.6±14.9 mmHg 
for aliskiren versus telmisartan, respectively, in the CASP 
randomised set (Figure 1(b)). Two days following with-
drawal, change in mean CASP was −1.9±1.7 mmHg with 
aliskiren and +0.4±1.7 mmHg with telmisartan, with LSM 
change between-treatment difference of −2.4±2.4 mmHg 
(95% CI: −7.1, 2.3; p = 0.324). Mean change in CASP 
from baseline following the 7-day withdrawal period was 
−0.7±1.2 mmHg for aliskiren. In contrast, an increase in 
CASP of +5.5±1.3 mmHg was observed upon telmisartan 
withdrawal. The LSM change between-treatment differ-
ence in CASP from baseline to day 7 of withdrawal was 
−6.2±1.8 mmHg (95% CI: −9.7, −2.7), which was a statis-
tically significant and potentially clinically relevant differ-
ence in favour of aliskiren (p < 0.0001) (Figure 1(c)). It is 
interesting to note that despite a higher baseline CASP 
value in the aliskiren compared to the telmisartan group, 
mean CASP decreased following aliskiren withdrawal 
while it increased upon telmisartan withdrawal across the 
7-day withdrawal period in the CASP randomised set.
At baseline for the treatment withdrawal period, mean 
seated CASP values were very similar between both treat-
ment groups in the CASP completer set (aliskiren, 
129.4±15.3 mmHg; telmisartan, 129.3±15.4 mmHg), as 
shown in Figure 2(b). Two days following withdrawal, 
mean CASP remained unchanged with aliskiren (−0.8±2.5 
mmHg) and increased with telmisartan (+2.1±2.6 mmHg), 
the LSM change between-treatment difference being 
−2.9±3.7 mmHg (95% CI: −10.2, 4.4; p = 0.436). Mean 
change in CASP from baseline following the 7-day with-
drawal period was −0.4±1.6 mmHg for aliskiren. In con-
trast, an increase in CASP of +4.6±1.7 mmHg was 
observed with telmisartan withdrawal. The LSM change 
Figure 2. (a) Mean msSBP, (b) mean CASP, (c) LSM change in CASP and (d) mean MASBP from end of treatment to end of 
withdrawal (day 7 of withdrawal) for the CASP completer set.
*p = 0.041 (aliskiren vs. telmisartan). Error bars indicate 95% CI. CASP, central aortic systolic pressure; LSM, least-squares mean; MASBP, mean 
ambulatory SBP; msSBP, mean sitting systolic blood pressure.
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between-treatment difference in CASP from baseline to 
day 7 of withdrawal was −4.9±2.4 mmHg (95% CI: −9.6, 
−0.2), which was a statistically significant and potentially 
clinically relevant difference in favour of aliskiren 
(p = 0.041) (Figure 2(c)).
Changes in 24-hour ABPM
At baseline for the withdrawal period, MASBP was 
133.3±11.6 mmHg and 132.7±12.2 mmHg for aliskiren 
and telmisartan, respectively, in the CASP randomised set 
(Figure 1(d)). Across the 7-day withdrawal period, MASBP 
changed little with aliskiren (+1.9±0.7 mmHg). In con-
trast, an increase in MASBP was seen 7 days following 
telmisartan withdrawal (+6.3±0.7 mmHg), with a signifi-
cant between-treatment difference (−4.4±1.0 mmHg; 95% 
CI: −6.4, −2.5; p < 0.0001), in favour of aliskiren.
At baseline for the treatment withdrawal period, 
MASBP was 135.2±10.5 mmHg and 136.6±11.8 mmHg 
for aliskiren and telmisartan, respectively, in the CASP 
completer set (Figure 2(d)). Across the 7-day withdrawal 
period, MASBP changed little with aliskiren (+1.2±1.1 
mmHg). In contrast, an increase in MASBP was seen 7 
days following telmisartan withdrawal (+5.5±1.2 mmHg), 
with a significant between-treatment difference (−4.3±1.7 
mmHg; 95% CI: −7.5, −1.0; p = 0.010), in favour of 
aliskiren.
Changes in PRA and aldosterone 
levels
Plasma biomarkers were analysed as an indication of treat-
ment response. Accordingly, the response of biomarkers 
from end of the treatment period to end of the withdrawal 
period is presented.
In the CASP randomised set, PRA levels increased dur-
ing 12 weeks of treatment with telmisartan, while it 
decreased in patients receiving aliskiren (Figure 3(a)). 
Seven days following treatment withdrawal, PRA returned 
towards baseline with both aliskiren and telmisartan in the 
CASP randomised set. Similarly, in the CASP completer 
set, 12 weeks of treatment was associated with an increase 
in PRA for patients receiving telmisartan, whilst PRA was 
suppressed in patients receiving aliskiren. Seven days fol-
lowing treatment withdrawal, PRA returned towards base-
line values with both treatments in the CASP completer set 
(Figure 4(a)).
In the CASP randomised set, 12 weeks of treatment was 
associated with a decrease in plasma aldosterone levels for 
both treatments. Plasma aldosterone increased during the 
7-day withdrawal period for both treatments (Figure 3(b)). 
The increase in aldosterone was greater following with-
drawal of telmisartan compared to aliskiren, which was 
statistically significant (p = 0.013). In the CASP completer 
set, 12 weeks of treatment was associated with a marked 
reduction in plasma aldosterone levels for both treatments. 
Plasma aldosterone increased during the 7-day withdrawal 
period for both treatments (Figure 4(b)). There was a 
greater increase in aldosterone following withdrawal of 
telmisartan compared to aliskiren, which did not achieve 
significance (p = 0.11). However, the clinical implications 
of differences in effect on RAAS components are not 
known.
Discussion
This study investigated the effects of simulating a period 
of non-adherence to BP-lowering medication on the sus-
tainability of BP control by withdrawing treatment over a 
7-day period. Two different treatments inhibiting the 
Figure 3. Mean changes in (a) plasma renin activity (PRA) and (b) plasma aldosterone from end of treatment to end of withdrawal 
(day 7 of withdrawal) for the CASP randomised set. Results are expressed as geometric means and error bars indicate 95% CI.
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RAAS were used for BP lowering, and the effects of treat-
ment withdrawal on both brachial pressure and CASP are 
reported here. The study demonstrates sustained control of 
both brachial and central BP even after 7 days of aliskiren 
withdrawal in the CASP completer and randomised sets. In 
contrast, both brachial and central BP increased gradually 
by 4-5 mmHg over the same time period following with-
drawal of telmisartan, indicating a gradual loss of BP con-
trol over the withdrawal period. This is the first reported 
data on the effects of treatment withdrawal on both bra-
chial and central aortic pressure and extends the previously 
reported observations of differential effects of treatment 
withdrawal on brachial BP and 24-hour ambulatory bra-
chial BP in the ASSERTIVE study.13,18
The primary focus of this study was a comparison 
between treatments for the change in seated CASP fol-
lowing treatment withdrawal, i.e. from the end of the 
12-week treatment period to day 2 and to the end of the 
7-day treatment withdrawal period in the CASP com-
pleter patients set. To complement the results from the 
CASP completer patients set, we also report changes in 
seated CASP following treatment withdrawal in the 
CASP randomised set. The primary endpoint showed sta-
tistical significance in favour of aliskiren over telmisar-
tan in the longevity of CASP control, with little change in 
CASP during the 7-day period following aliskiren with-
drawal in both CASP completer and randomised sets. 
Moreover, data from the present study illustrate that the 
pattern of change for brachial BP and CASP was broadly 
similar following withdrawal of either treatment. From 
this data it would seem that conventional monitoring of 
either brachial or central pressure is sufficient to deter-
mine the haemodynamic consequences of treatment with-
drawal as these changes occur in parallel during this 
period. This concept is also supported by the pattern of 
change for ambulatory brachial BP across the treatment 
withdrawal period, which was similar to that seen for 
both seated brachial BP and CASP in the CASP com-
pleter as well as in the CASP randomised sets.
With regard to the longevity of BP lowering across the 
treatment withdrawal period, aliskiren and telmisartan are 
both regarded as long-acting drugs from their respective 
classes. As reported previously, both drugs were very 
effective in decreasing brachial BP in the overall popula-
tion.19,20 In the present study, both treatments reduced BP 
to the same level following 12 weeks of treatment, such 
that the baseline brachial and central pressures for the 
withdrawal period did not differ between treatment arms. 
Moreover, brachial and central pressures remained propor-
tional across the withdrawal period for both treatments, i.e. 
there was no evidence of differential effects between the 
treatments.
Other studies investigating the influence of simulated 
non-adherence have assessed effects only on brachial BP 
and have used shorter treatment withdrawal time periods, 
typically 24–48 hours. Depending on the treatment regi-
men investigated, these studies have generally demon-
strated short-term maintenance, or partial loss of BP 
control with increases of 4-5 mmHg occurring over a short 
period of time.19 Data from the present study demonstrate 
consistency with previous findings over a 2-day treatment 
withdrawal period, and extend the same over a 7-day with-
drawal period, demonstrating loss in both brachial and 
central BP control upon telmisartan withdrawal but little 
change upon aliskiren withdrawal. These data demonstrate 
the sustained duration of action of aliskiren on seated bra-
chial BP, CASP and brachial ambulatory BP across the 
prolonged treatment withdrawal period of 7 days.
Figure 4. Mean changes in (a) plasma renin activity (PRA) and (b) plasma aldosterone from end of treatment to end of withdrawal 
(day 7 of withdrawal) for the CASP completer set. Results are expressed as geometric means and error bars indicate 95% CI.
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Persistence in the BP-lowering response to aliskiren 
and telmisartan is consistent with the pattern of biomarker 
activity monitored across the treatment withdrawal period 
in the CASP completer and the CASP randomised sets. As 
expected, PRA showed a divergent response over the 
12-week treatment period. As demonstrated previously, 
up-regulation of PRA was observed following active angi-
otensin receptor blockade,13,21 which results from stimula-
tion of renin secretion in the juxtaglomerular apparatus 
(JGA) in response to elevated circulating angiotensin II 
levels.22 In contrast, PRA was suppressed during active 
treatment with aliskiren, thereby reflecting inhibition of 
plasma renin. The extent of inhibition of PRA with 
aliskiren was similar to that reported previously.21 
Following treatment withdrawal, PRA returned towards 
baseline levels; however, the extent of this restoration 
appeared to differ between treatments. Thus, at the end of 
the 7-day withdrawal period, PRA reduced toward base-
line levels in patients previously randomised to telmisar-
tan, while there were signs of continued PRA suppression 
for patients previously randomised to aliskiren.
Active treatment was associated with suppression of 
plasma aldosterone levels, which returned to near-baseline 
levels at the end of the 7-day treatment withdrawal period 
for patients previously randomised to telmisartan. In con-
trast, a trend towards continued suppression of plasma 
aldosterone throughout the 7-day withdrawal period was 
evident in patients previously randomised to aliskiren. 
These data imply sustained inhibition of the RAAS with 
aliskiren withdrawal, while RAAS activity was gradually 
restored upon telmisartan withdrawal, and is consistent 
with other findings using these treatment types.7,13
Persistence in the BP lowering and aldosterone lower-
ing effects of aliskiren over the 7-day withdrawal period is 
consistent with tissue localisation studies with this drug. 
Animal studies indicate persistent accumulation of 
aliskiren in the kidney.23 A tissue distribution study in 
humans indicates affinity for lipophilic tissues,11 providing 
a likely rational for the sustained effects of aliskiren on 
RAAS and BP lowering. Typical half-lives for ARBs have 
been reported to be between 5 (eprosartan, valsartan) and 
24 (telmisartan) hours. The relatively long half-life for tel-
misartan is consistent with the slow restoration of BP and 
biomarker activity in this study.
This study has limitations that must be acknowledged. 
Central pressure was measured non-invasively as it was 
neither practical nor appropriate to use invasive measure-
ments with frequent visits in this study population. As this 
population was late middle-aged and predominantly white 
or Asian, these findings may not be applicable to young or 
black patients with hypertension. As this was a sub-study 
embedded within the ASSERTIVE trial, and as only 94 out 
of 303 participants had valid central BP measurements at 
every time point, this study was not powered to investigate 
the impact of treatment withdrawal on effects beyond BP 
lowering, such as cardiovascular outcomes. Therefore, the 
clinical implications of the differences observed in BP 
upon treatment withdrawal are not known.
In conclusion, we report for the first time the impact of 
treatment withdrawal on both brachial and central aortic 
pressure, demonstrating that both respond proportionately, 
and that brachial BP is a reasonable surrogate for changes 
in central pressure following withdrawal of these medica-
tions. The importance of such properties with regard to 
cardiovascular protection needs further investigation.
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